Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening
International Journal of Neonatal Screening · 26.06.2026 · 12 (3) · 47
DOI: 10.3390/ijns12030047 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 26.06.2026. Verfasst von Yuki Ueda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hokkaido University Hospital, North 14, West 5, Kita-Ku, Sapporo 060-8648, Hokkaido, Japan. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MHLW Research Program on Rare and Intractable Disease, JSPS KAKENHI.
Abstract (Originalsprache)
Enzyme replacement therapy (ERT) for central nervous system symptoms and newborn screening (NBS) is available in Japan for patients with mucopolysaccharidosis type II (MPS II). Of 12 suspected cases identified through the NBS program, 3 patients were diagnosed with neuronopathic MPS II (2 directly from the screened cohort and 1 affected sibling). We reviewed the clinical courses of these patients, who were treated with intracerebroventricular (ICV) ERT using idursulfase beta (Hunterase®) followed by umbilical cord blood transplantation (CBT). Heparan sulfate (HS) in the cerebrospinal fluid (CSF) was longitudinally measured as a therapeutic biomarker, and developmental age was evaluated. All patients achieved successful engraftment with no severe complications, except for one patient with sinusoidal obstruction syndrome. The CSF HS concentration showed a temporary increase during the ERT discontinuation period, which can be attributed to CBT, and a subsequent reduction after the resumption of ICV-ERT. The patients exhibited age-appropriate development. The pattern of change in HS indicates the importance of continuing ICV-ERT even after hematopoietic stem cell transplantation. The study results demonstrate that the combination of ICV-ERT and CBT may yield promising outcomes in patients with neuronopathic MPS II, underscoring the importance of early intervention through NBS.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatrics, Hokkaido University Hospital, North 14, West 5, Kita-Ku, Sapporo 060-8648, Hokkaido, Japan.
- Hokkaido Pharmaceutical Association Public Health Examination Center, Hiragishi 1-jo, 8-chome, Toyohira-Ku, Sapporo 062-0931, Hokkaido, Japan.
- Department of Genomic Medicine, Saitama Medical University Hospital, Morohongo 38, Moroyamamachi, Iruma-gun, Saitama 350-0451, Saitama, Japan.
ORCID-Profile: Yuki Ueda, Shinsuke Hirabayashi, Yukayo Terashita, Atsushi Manabe, Kiyoshi Egawa
Förderung
- MHLW Research Program on Rare and Intractable Disease
- JSPS KAKENHI
Zitieren
APA
Ueda, Y., Hirabayashi, S., Miura, M., Yamada, S., Nakakubo, S., Nakajima, M., Goto, T., Abe, J., Terashita, Y., Manabe, A., Okuyama, T., & Egawa, K. (2026). Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening. International Journal of Neonatal Screening, 12(3), 47. https://doi.org/10.3390/ijns12030047
Vancouver
Ueda Y, Hirabayashi S, Miura M, Yamada S, Nakakubo S, Nakajima M, et al. Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening. International Journal of Neonatal Screening. 2026;12(3):47. doi:10.3390/ijns12030047
BibTeX
@article{Ueda2026,
author = {Ueda, Yuki and Hirabayashi, Shinsuke and Miura, Masayuki and Yamada, Satoshi and Nakakubo, Sachiko and Nakajima, Midori and Goto, Takeru and Abe, Jutaro and Terashita, Yukayo and Manabe, Atsushi and Okuyama, Torayuki and Egawa, Kiyoshi},
title = {Combined Intracerebroventricular Enzyme Replacement and Cord Blood Transplantation in Patients with Mucopolysaccharidosis Type II Diagnosed Through Newborn Screening},
journal = {International Journal of Neonatal Screening},
year = {2026},
volume = {12},
number = {3},
pages = {47},
doi = {10.3390/ijns12030047}
}
EUVIMED